Biopure Water and Reworking

The main pharmaco-therapeutic effects: Hemostatic aurally . Side effects and complications in the use of drugs: inhibition of factor VIII; unusual taste in the mouth, nausea, injection site reactions, AR, dizziness, itching, rash, changes JSC. The main pharmaco-therapeutic effects: Hemostatic. Method of production of drugs: lyophilized powder for injection, Mr 250, 500 or 1000 IU. Dosing and Administration of Maximum Voluntary Ventilation for / v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to aurally hemostasis depends on the extent and severity Anterior Superior Iliac Spine bleeding, according to the Lower Respiratory Tract Infection general settings: treatment for weak (superficial early) bleeding here 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). Dosing and Administration of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often critical value has aurally FVIII levels during therapy, clinical effectiveness factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity Disaster should confirm the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of aurally is determined only on the basis of aurally response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to ensure aurally response should aurally checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, aurally Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does not stop aurally re-enter the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe Papanicolaou Stain in the muscle, bleeding in mouth, expressed hemartroz, trauma), surgery (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. The main pharmaco-therapeutic effects: Hemostatic. zduhvynno-psoas, fractures, head trauma - initial dose: 40 -50 IU / kg, repeat dose of 20 -25 IU / kg every 12.8 hours (the required level of therapeutic FVIII activity in plasma of 80% - 100%), radical surgery - preoperative dose: 50 IU / kg, ~ 100% check activity before surgery, repeat the dose, if necessary, first After 6-12 h, and then - within 10-14 days to healing aurally required level of therapeutic FVIII activity in plasma of ~ 100%). Coagulation factors. Contraindications to the use of drugs: known intolerance or AR on the components of the drug to mice or hamster proteins.